Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Name: Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
Creator: Ignace Vergote
Published: 2020-03-31T15:28:20.917Z
Keywords: Drug Therapy for Ovarian Cancer

Vergote, Ignace

doi:10.17632/yj4byrkjmj.1

Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Published: 31 March 2020| Version 1 | DOI: 10.17632/yj4byrkjmj.1

Contributor:

Ignace Vergote

Description

Protocol and SAP

Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Description

Files

Categories

Licence